Summary
146.88 2.84(1.97%)07/17/2025
ICON Public Limited Company (ICLR)
ICLR reported last earnings on 2025-04-30 after the market. An EPS of $3.19 was observed compared to an estimated EPS of $3.11, resulting in a surprise value of $0.08. A revenue of $2,001 million was observed compared to an estimated revenue of $2,008 million, resulting in a surprise value of $-6 Million.
ICON Public Limited Company (ICLR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -2.47 | -2.42 | 3.54 | 5.43 | -25.86 | -56.01 | -23.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | A- |
| Recommended Rating | Buy |
| DCF | Strong Buy |
| ROE | Neutral |
| ROA | Buy |
| Debt/Equity | Sell |
| P/E | Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 143.25 | |
| Open | 148.10 | |
| High | 148.73 | |
| Low | 142.48 | |
| Volume | 1,370,996 | |
| Change | -3.63 | |
| Change % | -2.47 | |
| Avg Volume (20 Days) | 1,179,855 | |
| Volume/Avg Volume (20 Days) Ratio | 1.16 | |
| 52 Week Range | 125.10 - 345.86 | |
| Price vs 52 Week High | -58.58% | |
| Price vs 52 Week Low | 14.51% | |
| Range | 0.00 | |
| Gap Up/Down | -5.78 | |
Profitibility | ||
| Market Capitalization (Mln) | 12,131 | |
| Revenue per share | 100.1719 | |
| Net Income per share | 9.2704 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 15.8439 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/16 11:06 EST - zacks.com
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/16 07:15 EST - businesswire.com
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical...
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical...
07/08 09:47 EST - fool.com
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (ICLR 0.92%) by selling 16,096 shares. The transaction was valued at $2.58 million.
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (ICLR 0.92%) by selling 16,096 shares. The transaction was valued at $2.58 million.
07/07 07:15 EST - businesswire.com
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge...
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge...
06/25 06:36 EST - seekingalpha.com
ICON: With A 57% Drop, Trump Legislation, And Debt Reduction, Is The Stock Undervalued?
The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to repurchase $750 million of its outstanding common shares.
ICON: With A 57% Drop, Trump Legislation, And Debt Reduction, Is The Stock Undervalued?
The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to repurchase $750 million of its outstanding common shares.
06/23 06:30 EST - businesswire.com
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Second Quarter 2025 Earnings Conference Call.
ICON plc Schedules Second Quarter 2025 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Second Quarter 2025 Earnings Conference Call.
06/02 12:49 EST - businesswire.com
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm.
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm.
06/02 11:26 EST - zacks.com
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
06/02 04:12 EST - prnewswire.com
ICLR Shareholders Have the Right to Lead the ICON Public Limited Company Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ICLR
LOS ANGELES , June 2, 2025 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of the federal securities laws. Shareholders who purchased the Company's securities between July...
ICLR Shareholders Have the Right to Lead the ICON Public Limited Company Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ICLR
LOS ANGELES , June 2, 2025 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of the federal securities laws. Shareholders who purchased the Company's securities between July...
05/27 10:01 EST - https://www.prnewswire.com
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ -- According to a new market research...
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®
Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ -- According to a new market research...
05/27 08:30 EST - businesswire.com
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the William Blair 45th Annual Growth Stock Conference.
ICON plc to Present at the William Blair 45th Annual Growth Stock Conference
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the William Blair 45th Annual Growth Stock Conference.
05/19 16:15 EST - businesswire.com
ICON releases its ICON Cares 2024 Report
DUBLIN--(BUSINESS WIRE)--ICON releases its ICON Cares 2024 Report.
ICON releases its ICON Cares 2024 Report
DUBLIN--(BUSINESS WIRE)--ICON releases its ICON Cares 2024 Report.
05/07 07:27 EST - businesswire.com
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for...
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for...
05/05 08:01 EST - prnewswire.com
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall LAW FIRM
LOS ANGELES , May 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR)  for violations of §§10(b) and 20(a) of the Securities...
ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall LAW FIRM
LOS ANGELES , May 5, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR)  for violations of §§10(b) and 20(a) of the Securities...
05/02 02:42 EST - seekingalpha.com
ICON Public Limited Company (ICLR) Q1 2025 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q1 2025 Earnings Call Transcript May 1, 2025 8:00 AM ET Company Participants Kate Haven - Vice President, Investor Relations Steve Cutler - Chief Executive Officer Nigel Clerkin - Chief Financial Officer Barry Balfe - Chief Operating Officer Conference...
ICON Public Limited Company (ICLR) Q1 2025 Earnings Call Transcript
ICON Public Limited Company (NASDAQ:ICLR ) Q1 2025 Earnings Call Transcript May 1, 2025 8:00 AM ET Company Participants Kate Haven - Vice President, Investor Relations Steve Cutler - Chief Executive Officer Nigel Clerkin - Chief Financial Officer Barry Balfe - Chief Operating Officer Conference...
05/01 10:20 EST - zacks.com
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.
ICON's Q1 Earnings Surpass Estimates, Revenues Lag, Stock Down
ICLR posts mixed results in the first quarter of 2025 due to ongoing clinical development and market volatility.